ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

NCI advisors approve $144 million program for nanotechnology centers, R01 grants, training. Three to five consortia envisioned.

July 16, 2004

Health Organizations: ACS Statement Supports funding of Research On Human Stem cells

December 17, 1999

NCI Plans Briefing Oct. 8 In St. Louis for SPORE Applicants

August 23, 1991

FDA Gives Accelerated Approval To Tykerb For Metastatic Breast Cancer

February 5, 2010

In Brief: Over Half Of Ovarian Cancer Patients Staged Incorrectly; Senate Gets Funding Resolution

April 12, 1985

Five Awards Expected In Annual CCP Review; 21 Applicants Compete For Limited Funding

February 1, 1991